Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hims & Hers Health's enterprise value is MXN118,128 Mil.
Hims & Hers Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was MXN716 Mil. Therefore, Hims & Hers Health's EV-to-EBITDA for today is 165.08.
The historical rank and industry rank for Hims & Hers Health's EV-to-EBITDA or its related term are showing as below:
MEX:HIMS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -162.76 Med: -9.53 Max: 2488.47
Current: 181.22
During the past 7 years, the highest EV-to-EBITDA of Hims & Hers Health was 2488.47. The lowest was -162.76. And the median was -9.53.
MEX:HIMS's EV-to-EBITDA is ranked worse than 97.45% of 746
companies
in the Drug Manufacturers industry
Industry Median: 13.015
vs MEX:HIMS: 181.22
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Hims & Hers Health (MEX:HIMS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hims & Hers Health's PE Ratio (TTM) for today is calculated as:
Hims & Hers Health's share price for today is MXN480.00.
Hims & Hers Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Hims & Hers Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:HIMS vs LNTH, AMRX, LQDA: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hims & Hers Health EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's EV-to-EBITDA falls into.
Hims & Hers Health's current Enterprise Value is MXN118,128 Mil.
Hims & Hers Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN716 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hims & Hers Health (MEX:HIMS) has a EV-to-EBITDA of 165.08 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hims & Hers Health. According to the industry distribution chart, Hims & Hers Health ranks #727 out of 746 companies in the Drug Manufacturers industry, placing it in the top 97.5%.
Is Hims & Hers Health's EV-to-EBITDA too high?
Hims & Hers Health's current EV-to-EBITDA is 165.08. The Drug Manufacturers industry median EV-to-EBITDA is 13.02. Hims & Hers Health's value of 165.08 is 1168.4% above this industry median. Based on the distribution chart, Hims & Hers Health ranks #727 out of 746 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hims & Hers Health has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's EV-to-EBITDA compare to LNTH and AMRX?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #727 out of 746 companies for EV-to-EBITDA. This places Hims & Hers Health in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. Hims & Hers Health's value of 165.08 is 1168.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.02, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hims & Hers Health's current EV-to-EBITDA of 165.08 is 1168.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hims & Hers Health. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hims & Hers Health's current EV-to-EBITDA is 165.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (MEX:HIMS) is currently considered Possible Value Trap. The stock's GF Value™ is MXN707.80, compared to a current price of MXN480.00 — trading 32.2% below its estimated fair value. The current EV-to-EBITDA is 165.08 and 1168.4% above the Drug Manufacturers industry median of 13.02. Hims & Hers Health's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Hims & Hers Health (MEX:HIMS), the current EV-to-EBITDA is 165.08 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (MEX:HIMS) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of MXN480.00 is trading 32.2% below its estimated GF Value™ of MXN707.80.
GuruFocus considers Hims & Hers Health to be Possible Value Trap.
Key valuation signals for MEX:HIMS:
EV-to-EBITDA: 165.08
GF Value™: MXN707.80 vs. price of MXN480.00 (32.2% below fair value)
Industry Position: 1168.4% above the Drug Manufacturers median (#727 of 746)
No single metric tells the full story. See the MEX:HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
55GF Score
Get the complete analysis for MEX:HIMS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:HIMS has been successfully added to your 
